U.S. Markets open in 6 hrs 3 mins

Bovie Medical Corporation (BVX)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
2.39-0.01 (-0.42%)
At close: 3:59PM EDT
People also watch
AOICASMPDEXTSTCRVP
  • B
    Bikerider79
    Bikerider79
    Shareholders about to get it up the wazoo, big time. From the proxy statement:
    AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK, HAVING A PAR VALUE OF $.001 PER SHARE ("COMMON STOCK"), FROM FORTY MILLION (40,000,000) SHARES TO SEVENTY-FIVE MILLION (75,000,000) SHARES OF COMMON STOCK.
    Share price will under $1 when this happens -- but I’m sure they’re already planning a reverse split to destroy shareholders even more. And look at those bonuses paid to this genius management! Wow!!!
    The have no shame.
  • B
    Bikerider79
    Bikerider79
    Revenue can be gamed – if management doesn’t care about what it means to the bottom line. The widening net loss is worrisome, but cash burn is more worrisome. Last year, Gerhson and the CFO said Bovie would be cash-flow neutral by the end of 2016 and cash-flow positive in 2017. A lie? Or just incompetence? Like almost everything else they have forecast and projected, from hospital approvals to channel partners to no need for further dilutions, they are not to be trusted. No wonder there is no interest in this stock. They are burning cash when they said they would be generating cash, and this is a destructive management that doesn’t have a clue.
  • B
    Buster
    Buster
    LOL. Theyre trying another presentation! They have nothing to present, except how to burn cash.
    Imageheckyeahreactiongifs
  • B
    Bikerider79
    Bikerider79
    This company and especially its management has always been a little fishy and shifty. For a long time, the CEO has been pitching the investment thesis to naïve and unquestioning shareholders that jplasma is a high-margin, high-profit product. Yet in Q2, revenue in that segment was higher and still the Y-over-Y net loss widened, even wider than analysts estimate. Obviously, something is wrong. It was apparent in the Hologic debacle that Hologic was signaling that jplasma is not a financially viable product. It looks like that is apparent with Q2 earnings. Unless there is a complete management shakeup, the stock will probably be under $1 by the end of the year. It may already be too late.
  • B
    Bob
    Bob
    A good acquisition target for the JPlasma technology?
  • B
    Bikerider79
    Bikerider79
    Revenue was higher although the net loss widened and was worse than analysts’ estimates (sure, nothing to worry about there.) Cash burn continues, down from $14.5M in Q4, $11.5M in Q1, and now at $10.2M after Q2 (I thought they were supposed to be cash flow neutral? Well, so much for that). No mention of sales channel partner (Gershie promised one by July. Well, so much for that, too.) Also, international sales down 29%, so why did these geniuses invest in Bovie Bulgaria? OEM down more than estimated (exactly as I said it would be.) The whole initial strategy of getting jplasma into hospitals, which would have been lucrative, seems to have been largely disbanded. They’re going nowhere. But give yourself a raise, Gershie!
  • S
    Stkpikr
    Stkpikr
    Good traction in plasma and that is the future. Lots of new products coming to market. This company is worth significantly more than its market value. Should be $6 in a year.
  • B
    Bikerider79
    Bikerider79
    So, Gershie, where's your promised channel partner? Earnings in a week. Tick...tick...tick
  • B
    Bikerider79
    Bikerider79
    Gershon on March 10: “We do expect that we will have a sales channel partner in place for J-Plasma, for GYN based on the conversation to-date the interest level seems high and we think that we’ll likely have a sales channel partner in place … I think it’s pretty safe to say if we have one in place it will probably occur within two to four months from now probably a safe range.”
    He had no sales channel partners then, he has none now. Just another tall tale from the pipsqueak carnival huckster, like all the others.
  • B
    Bikerider79
    Bikerider79
    Under $2, as I predicted. BVX shares are now lower than when Gershon was named CEO in December 2013, but it’s even a sadder story for shareholders. Gershon has slashed shareholder equity by almost 50 percent, doubling the number of outstanding shares from about 17 million to more than 30 million. To justify this catastrophic dilution, Bovie revenue would have had to double, which, needless to say, never will happen. Outside of paying salaries, bonuses and other compensation, where really did that money go? Meanwhile, the jplasma launch was more than a failure, it was a debacle. The overpaid Geshon and McCarthy continue to destroy the company, and even more shamefully, the past incompetent management team of Makrides, Saron and Citronowicz remain on the payroll and pull down lavish salaries and benefits considering the size and lack of performance of the company. Question for shareholders: When does incompetence rise to the level of criminality? When does giving information that you as a corporate executive should know is patently false become fraud?
  • B
    Bikerider79
    Bikerider79
    Gershon’s “guidance” is so implausible it borders on fraudulent. He is predicting “60% to 80% year-over-year” growth in advanced energy (jPlasma), yet jplasma sales have declined sharply from $1.4M in Q3-2016 to $970,000 in Q4-2017 to a shockingly low $607,000 in Q12017. (This number is even less than Q2-2016!) He also admits that OEM revenue will decline 25% to 35% year-over-year, which means -- considering this incompetent nonentity’s track record -- the decline will be even more. His overall revenue “guidance” of a gain of 5-10 percent year-over-year is a fairytale. Maybe he’s assuming that the scratch-off lottery ticket he bought will pay off and that’s part of the “guidance”? Actually, buying lottery tickets has a better chance of paying off than Bovie stock. Can someone tell me how this inept pipsqueak carnival huckster and his Chief Noncommercialization Officer are allowed to keep their jobs? If they’re waiting for the stock to dip below $1, they won’t have to wait too much longer.
  • B
    Bikerider79
    Bikerider79
    Anyone who held on after the Hologic deal blew up so fast was crazy, but the signs of the destruction of this once promising company have been going on for years. In the past, Gershon would chirp about jPlasma “metrics” such as hospital approvals, generators sold, generators in use, handpieces sold, etc., etc. All these metrics indicate if a product is selling -- or not selling. Not surprisingly, this inept CEO doesn’t even bother with any metrics or data or numbers anymore, an indication jplasma is a failure. He has very little stake in BVX stock, so why should he care about the stock price. He and his “management team” can’t get bonuses by hitting performance targets, but they got bonuses for successful dilutions -- in effect stealing money from shareholders and putting it in their pockets. The fact that no one has gotten fired indicates the Board knows nothing can save this company, so they’ll just all go down with the ship -- collecting hefty paychecks until it finally sinks.
  • B
    Bikerider79
    Bikerider79
    Earnings are an unmitigated disaster. JPlasma sales fell 37% sequentially, and have fallen for 2 straight quarters. Yet, the pipsqueak carnival huckster on March 9, when the 1st quarter was 75% over and he knew how the quarter would look, said “We expect sequential growth quarter-over-quarter and that includes Q1.” Which means, either a) Bovie didn’t sell a single jplasma product from March 10-31; b) people returned jplasma products from March 10-31; c) Gershon is delusional; d) Gershon was lying. Now you know why they did they dilution. They are running out of money. This scam has been going on for more than 10 years now. Tomorrow, the stock crashes. It is all over for Jplasma, it is probably all over for Bovie.
  • B
    Bikerider79
    Bikerider79
    As predicted, the stock is cratering. The “guidance” fraud is the same transparent trick Gershon pulled after the Hologic deal blew up, when he ordered a press release “confirming” an outlook that was false. And on March 9, this incompetent nonentity actually said sequential revenue in Q1 would be higher, when he had to know that was false. As for the conference call, Gershon made sure to hog all the time with inanities so there would be less time for questions, which he knew he couldn’t answer. And where was the chief noncommercial officer on the call? He usually likes to chime in with alternative-facts, but I didn’t hear him at all. Maybe he was planning the next dilution, when Bovie is at 10 cents a share.
  • P
    PAco
    PAco
    136,000 shares short. 23,200,000 float? No place to go but up!
  • B
    Bikerider79
    Bikerider79
    Been aware for a while, but it’s all the same. Nothing ever changes. The useless Wise still posts his useless links to useless patents, while also posting the same alt-nut conspiracy theories he’s done for the past 10 years. Makrides, Saron and Moshe still draw huge paychecks for doing -- what? Meanwhile, Bovie just sinks and sinks. The only chance they had was Hologic, and that blew up after just a few months. The rumors why it blew up, if true, are unsettling. Maybe carnival barker Gershon and chief noncommercialization officer McCarthy --AKA the Dilution Boys -- will address it at the next CC (Yeah, sure). It looks like Q1 will be another disaster. But at least that will prevent the Dilution Boys from doing what they do best -- diluting their shareholders.
  • w
    wise2allofu
    wise2allofu
    Bike...you're as big of a jackass as Trump.
  • w
    wise2allofu
    wise2allofu
    Cold plasma sanitizing device
    Complete Patent Searching Database and Patent Data Analytics Services.
    www.freepatentsonline.com
  • A
    Andrea
    Andrea
    The scenarios are quite interesting at current levels for BVX. Yo you should really check out awe-someSTOCKS, they seem on point with their stocks.
  • t
    tom
    tom
    The top line was $300,000 less than what analysts had estimated. A miss, but not a big one. Horrific? No way. And J Plasma sales in 4Q vs. 3Q is comparing apples to oranges as 3Q benefitted from supplying Hologix with demos. So it is not that the 4Q was bad; it is just that the 3Q was clearly higher than usual due to the Hologix deal. So the comparisons are not valid.